World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
54598
World Ranking
5475
National Ranking
77

Overview

Miguel Martin is affiliated with the Complutense University of Madrid in Spain. Their research primarily focuses on Medicine and Biochemistry, Genetics and Molecular Biology, with substantial contributions to Oncology and related subfields. Their work spans advanced breast cancer therapies, HER2/EGFR in cancer research, breast cancer treatment studies, and cancer treatment and pharmacology.

The main fields of study associated with their publications include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields highlighted in their scientific output are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Genetics
  • Radiology, Nuclear Medicine and Imaging

The principal topics covered in their research consist of:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer-related Molecular Pathways
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics

Miguel Martin has contributed numerous articles published in various scientific journals. Frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • UNC Libraries

Among significant recent papers are:

  • Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer, 2021, npj Breast Cancer
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology
  • Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial, 2022, The Lancet Oncology
  • Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study, 2021, Annals of Oncology
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology

Their frequent co-authors include:

  • José Á. García-Sáenz
  • Hope S. Rugo
  • Nadia Harbeck
  • Masakazu Toi
  • Eva Ciruelos

Miguel Martin has also contributed to book publications, including a title published by Dykinson eBooks:

  • Envejecimiento, ética y derecho en un mundo globalizado: retos y perspectivas., 2023

Best Publications

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

    Jennifer K. Litton;Hope S. Rugo;Johannes Ettl;Sara A. Hurvitz

  • Adjuvant docetaxel for node-positive breast cancer.

    Miguel Martin;Tadeusz Pienkowski;John R Mackey;Marek Pawlicki

  • Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

    D. Slamon;W. Eiermann;N. Robert;T. Pienkowski

  • The Global Breast Cancer Burden: Variations in Epidemiology and Survival

    Gabriel N. Hortobagyi;Jaime de la Garza Salazar;Kathleen Pritchard;Dino Amadori

  • Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    Angelo Di Leo;Guy Jerusalem;Lubos Petruzelka;Roberto Torres

  • Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

    Aleix Prat;Maggie Chon U. Cheang;Miguel Martín;Joel S. Parker

  • A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

    Christos Hatzis;Lajos Pusztai;Vicente Valero;Daniel J. Booser

  • Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

    Judith Hugh;John Hanson;Maggie Chon U. Cheang;Torsten O. Nielsen

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy

  • Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial

    Jean Marc Nabholtz;Carla Falkson;Daniel Campos;Janos Szanto

  • Melatonin, mitochondria, and cellular bioenergetics.

    Darío Acuña-Castroviejo;Miguel Martín;Manuel Macías;Germaine Escames

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    Sara A. Hurvitz;Miguel Martin;W. Fraser Symmans;Kyung Hae Jung

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Ana Lluch
Ana Lluch University of Valencia
John R. Mackey
John R. Mackey University of Alberta
Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center
Masakazu Toi
Masakazu Toi Kyoto University
Carlos H. Barrios
Carlos H. Barrios Pontifical Catholic University of Rio Grande do Sul
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Dennis J. Slamon
Dennis J. Slamon University of California, Los Angeles
Pierfranco Conte
Pierfranco Conte University of Padua

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative medical career pathways and online degrees can provide greater flexibility and affordability for students in the USA. If you’re interested in pursuing advanced nursing roles, consider the cheapest bsn to dnp programs, which allow you to earn your Doctor of Nursing Practice without high tuition costs.

Pharmacy is another in-demand field. For those looking for a quicker route, the 3-year online pharmd programs make earning a Doctorate of Pharmacy both accessible and efficient for working professionals.

Healthcare administration and data roles are growing rapidly. With a health information management degree online, you can gain expertise in managing medical records and health data systems—an essential skill in today’s digital health landscape.

Entry-level options like medical billing and coding online courses open doors to quick certification and stable employment in the healthcare sector, often with the opportunity to work remotely.

Pursuing any of these online pathways can offer a practical alternative or supplement to traditional on-campus medical programs, helping you build a rewarding healthcare career.

Best Scientists Citing Miguel Martin

Trending Scientists

Recently Published Articles